Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Email this article to a Colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to My Articles & Searches Download to citation manager Citing Articles via HighWire Citing Articles via Google Scholar Articles by Howes, O. D. Articles by Pilowsky, L. S. Search for Related Content PubMed Citation Articles by Howes, O. D. Articles by Pilowsky, L. S. Neuroendocrinology Atypical Neuroleptics Schizophrenia Spectrum Disorders

A Prospective Study of Impairment in Glucose Control Caused by Clozapine Without Changes in Insulin Resistance

OBJECTIVE: This prospective study examines the effect of clozapine on glucose control and insulin sensitivity. METHOD: Glucose homeostasis was measured in nine female and 11 male patients with schizophrenia (mean age=30.5 years, SD=7.4) before clozapine treatment and after a mean of 2.5 months (SD=0.95) of clozapine treatment. Oral glucose tolerance and insulin levels were measured. Insulin resistance level was measured by the homeostasis model assessment. RESULTS: Eleven (55%) of the patients developed abnormal glucose control; the mean age of these patients was 30.2 (SD=7.1), and five were women. Patients’ insulin resistance at baseline (mean insulin resistance level=3.88, SD=2.93) was unaffected by clozapine. Mean fasting and 2-hour glucose levels significantly increased by 0.55 mmol/liter and 1.4 mmol/liter, respectively. There was no correlation between change in body mass index and change in fasting glucose levels. CONCLUSIONS: Clozapine impairs glucose control within 4 months of treatment, independent of changes in insulin sensitivity and body mass index.

This article has been cited by other articles:

				A.H. Barnett, P. Mackin, I. Chaudhry, A. Farooqi, R. Gadsby, A. Heald, J. Hill, H. Millar, R. Peveler, A. Rees, et al. Minimising metabolic and cardiovascular risk in schizophrenia: diabetes, obesity and dyslipidaemia J Psychopharmacol, June 1, 2007; 21(4): 357 - 373. [Abstract] [PDF]

				C. J. Tarrant Blood glucose testing for adults prescribed atypical antipsychotics in primary and secondary care Psychiatr. Bull., August 1, 2006; 30(8): 286 - 288. [Abstract] [Full Text] [PDF]

				D. Cohen, R. P. Stolk, D. E. Grobbee, and C. C. Gispen-de Wied Hyperglycemia and Diabetes in Patients With Schizophrenia or Schizoaffective Disorders Diabetes Care, April 1, 2006; 29(4): 786 - 791. [Abstract] [Full Text] [PDF]

				R. I. G. Holt, C. Bushe, and L. Citrome Diabetes and schizophrenia 2005: are we any closer to understanding the link? J Psychopharmacol, November 1, 2005; 19(6_suppl): 56 - 65. [Abstract] [PDF]

				V. J. Fedorowicz and E. Fombonne Metabolic side effects of atypical antipsychotics in children: a literature review J Psychopharmacol, September 1, 2005; 19(5): 533 - 550. [Abstract] [PDF]

Get information about faster international access.

Privacy Policy

Copyright © 2004 American Psychiatric Association. All rights reserved.

Home | Search | Current Issue | Past Issues | Subscribe | All APPI Journals | Help | Contact Us